Content about Novartis

November 21, 2012
FDA approves first flu vaccine manufactured by Novartis using cell culture technology

The Food and Drug Administration on Wednesday announced the approval of Novartis' Flucelvax, the first seasonal influenza vaccine licensed in the United States produced using cultured animal cells, instead of fertilized chicken eggs.

November 15, 2012
Branded generics transform the old into the new

In the classic Arabian Nights tale “Aladdin and the Magic Lamp,” the sorcerer who sold Aladdin the lamp containing the genie attempts to get it back by walking through the town where Aladdin and his wife live disguised as a merchant, trading “new lamps 
for old.” 


November 15, 2012
Generic drugs compete in game of differentiation

The year 2012 is coming to an end, and it’s been a big year for 
generic drugs.


November 15, 2012
NewsBytes — Chain Pharmacy, 11/19/12

The Food and Drug Administration has approved a generic drug for leukemia made by a subsidiary of Par Pharmaceutical Cos.


November 14, 2012
Novartis Consumer launches My Migraine Triggers app

Novartis Consumer Health on Wednesday announced the development of a convenient migraine trigger tracking tool, My Migraine Triggers App, with a neurologist.

November 8, 2012
FDA panel recommends approval for Novartis Cushing's disease drug

A Food and Drug Administration expert panel has voted unanimously in favor of approval for a Novartis drug for a rare endocrine disorder.

November 5, 2012
Watson-Actavis latest among generic M&As

In what its president and CEO called a “significant milestone,” Watson Pharmaceuticals announced last month that the U.S. Federal Trade Commission and European Commission had approved its acquisition of Swiss generic drug maker Actavis.

October 31, 2012
Sandoz starts phase-3 trial of biosimilar anemia drug

Generic drug maker Sandoz has started a late-stage clinical trial in the United States for a biosimilar treatment for anemia, the company said.

October 26, 2012
Novartis outsources production to bring back top-selling OTC brands to market

Progress at re-opening its manufacturing facility in Lincoln, Neb., has been slow-going, Novartis reported Thursday, but the company has contracted third-party manufacturers to resume production of Excedrin, Lamisil and Triaminic.

October 23, 2012
United Therapeutics awaits FDA decision on oral PAH drug as Sandoz seeks generic approval

The Food and Drug Administration is expected to decide at the end of this week whether to approve a new oral drug for pulmonary arterial hypertension made by United Therapeutics.

October 22, 2012
Watson, Actavis divest more drugs as condition for FTC merger approval

Watson Pharmaceuticals and Actavis will have to divest rights to almost two dozen drugs as a condition for U.S. regulatory approval of their $5.6 billion merger announced earlier this year, according to regulatory documents.

October 12, 2012
FDA approves Sandoz dermatology drug

The Food and Drug Administration has approved a drug made by Sandoz for treating symptoms of various skin diseases.

September 24, 2012
Sandoz launches authorized generic of Diovan HCT

Generic drug maker Sandoz has launched an authorized generic version of a drug used to treat hypertension.

September 21, 2012
FDA approves Mylan hypertension drug

The Food and Drug Administration has approved a blood pressure medication made by Mylan.

September 18, 2012
Mergers among generics cos. on the rise

Over the last few years of DSN’s coverage of the impending patent cliff and how it would affect the generic drug industry, IMS Health VP industry relations Doug Long predicted that the gradual commoditization of primary care drugs — long the lifeblood of generic drug makers — would lead to consolidation of the industry.


September 12, 2012
SoloHealth brings together veteran executive team in preparation for national kiosk launch

SoloHealth on Wednesday named Tim Kiss to serve as VP marketing — a new position at SoloHealth — as the company prepares for its nationwide rollout of the SoloHealth Station consumer kiosk this fall.

September 6, 2012
FDA advisory committee recommends approval for Novartis cystic fibrosis drug

A panel of Food and Drug Administration experts is recommending that the agency approve an experimental drug for cystic fibrosis made by Novartis, the Swiss drug maker said.

September 4, 2012
FDA approves smaller-dose Afinitor for rare brain tumor in children

The Food and Drug Administration has approved a new formulation of a cancer drug made by Novartis for a type of brain cancer in children, the agency said.

August 17, 2012
Generics contend in PPIs

Procter & Gamble’s Prilosec OTC still is the best-selling antacid on the market, with more than $252.7 million in annual sales for the 52 weeks ended July 8 across food, drug and mass (excluding Walmart), followed by fellow proton-pump inhibitor Novartis’ Prevacid 24HR ($104.1 million).


August 14, 2012
FDA approves formulation for 2012-2013 flu vaccines

The Food and Drug Administration has approved the formulation for the 2012-2013 flu vaccine, the agency said Monday.

August 13, 2012
Novartis drug appears effective in liver transplant patients

An experimental drug therapy under development by Novartis for liver transplant patients appears to provide similar efficacy and better kidney function, compared with a drug made by Astellas Pharma, according to results of a late-stage clinical trial.

August 6, 2012
Sandoz launches generic psoriasis treatment

Sandoz has launched a generic version of a topical medication used to treat psoriasis, the company said.

July 23, 2012
FDA approves Afinitor for advanced breast cancer

The Food and Drug Administration has approved a new use for a Novartis cancer drug.

July 18, 2012
Teva launches ADHD drug

Teva Pharmaceuticals has introduced a generic drug for treating attention deficit hyperactivity disorder, the company said.

June 21, 2012
Cough-cold season 
sure to be a volatile one

While no one can predict illness rates for the upcoming 2012-2013 cough, cold and flu season — unless maybe you’re reading out of the book of Nostradamus — one thing you can bank on is this: It’s going to be one volatile season.


© 2013 Drug Store News. All Rights Reserved.